TICKERNERD
Menu
SPRBSPRBHealthcare · Biotechnology

SPRB Stock Forecast: Spruce Biosciences, Inc. Price Predictions for 2026-2027

Last close, 28 Aug 2026
$61

The 7 Wall Street analysts covering Spruce Biosciences, Inc. hold a median 12-month price target of $142 — +133.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 28 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$181.9M
Ticker Nerd rank
28 / 100
Median analyst target
$142
Analysts covering
7
Revenue$0.0
Operating income−$12.0M
Net income−$12.3M
Free cash flow−$8.7M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Ticker Nerd rank

SPRB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Spruce Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Aug 2026
28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
76
Momentum
75
Size
70
Volatility
51
Accruals
43
Revisions
26
Quality
25
Value
24
Issuance
8

Growth (76): Sales and profits are climbing, and climbing faster than before.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SPRB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SPRB, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $104Median $142High $230

The green dot is the last close — the median target sits +133.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026GuggenheimMaintainsBuy$123 → $104
13 Aug 2026CitizensMaintainsMarket Outperform$150 → $144
13 July 2026B. Riley SecuritiesInitiatesBuy—
13 July 2026B. Riley SecuritiesInitiatesBuy$160
16 June 2026GuggenheimInitiatesBuy—
9 June 2026Jones TradingInitiatesBuy—
1 June 2026HC Wainwright & Co.MaintainsBuy—
14 May 2026CitizensMaintainsMarket Outperform—
27 Apr 2026Craig-HallumInitiatesBuy—
10 Mar 2026CitizensMaintainsMarket Outperform—
10 Mar 2026HC Wainwright & Co.ReiteratesBuy—
19 Feb 2026HC Wainwright & Co.MaintainsBuy—
23 Dec 2025OppenheimerInitiatesOutperform—
22 Dec 2025HC Wainwright & Co.AssumesBuy$220
3 Dec 2025Leerink PartnersUpgradeOutperform—
11 Nov 2025CitizensMaintainsMarket Outperform—
28 Oct 2025JMP SecuritiesUpgradeMarket Outperform—
21 Oct 2025Leerink PartnersMaintainsMarket Perform—
16 Apr 2025RBC CapitalMaintainsSector Perform—
16 Dec 2024HC Wainwright & Co.ReiteratesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SPRB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SPRB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

Spruce Biosciences, Inc. (SPRB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.2×

Cheaper than 83% of US stocks

Price / sales
—
Price / book
2.1×

Cheaper than 45% of US stocks

EV / EBITDA
−2.4×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−106.0%

Higher than 13% of US stocks

Return on assets
−40.0%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Spruce Biosciences, Inc. (SPRB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Spruce Biosciences, Inc. has a market value of $181.9M and an enterprise value of $93.3M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$37.2M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$29.3M.

  • Shares outstanding: 1.4M.

  • Trailing P/E: −1.2×; forward P/E: 7.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Spruce Biosciences, Inc. employs 22 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 28 Aug 2026

Data provided by Twelve Data

Peers

SPRB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SPRBSpruce Biosciences, Inc.$181.9M
28
HUMAHumacyte, Inc.$175.3M
17
CRBUCaribou Biosciences, Inc.$173.7M
58
MENSJyong Biotech Ltd.$175.9M
3
CNTNCanton Strategic Holdings, Inc.$171.2M
13
CDXSCodexis, Inc.$171.0M
67
KRROKorro Bio, Inc.$186.2M
27

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Spruce Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SPRB news & analysis

Spruce Biosciences Announces Launch of MPS3BStudy.com

Business Wire · 26 Aug 2026neutral

Spruce Biosciences announced the launch of MPS3BStudy.com, a dedicated online resource for families and caregivers of children with Sanfilippo Syndrome Type B (MPS IIIB). The website allows users to learn about the condition and register their interest in the study.

Why it matters — SPRB watchers would care because the initiative expands patient and caregiver outreach and may help support enrollment in the company's MPS IIIB study.

Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026

Business Wire · 24 Aug 2026positive

Spruce Biosciences announced it has completed two pre-BLA meetings with the FDA that support its plan to submit a Biologics License Application for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo syndrome. The company confirmed the BLA submission remains on track for Q4 2026.

Why it matters — The FDA meetings and confirmed timeline advance a key regulatory milestone for Spruce's lead TA-ERT candidate.

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Business Wire · 12 Aug 2026neutral

Spruce Biosciences reported its second quarter 2026 financial results and noted progress advancing TA-ERT toward a planned Biologics License Application submission in the fourth quarter.

Why it matters — The update signals the company is on track for a key regulatory milestone that could determine the near-term future of its lead product candidate.

Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

Business Wire · 12 Aug 2026positive

Cure Sanfilippo Foundation and the National MPS Society have agreed to make a combined $5.5 million strategic investment in Spruce Biosciences. The proceeds will be used to partially fund the TA-ERT EAP, helping to broaden patient access.

Why it matters — A SPRB watcher would care because the investment provides funding for the TA-ERT early access program, supporting expanded patient access to the company's therapy.

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

Business Wire · 3 Aug 2026neutral

Spruce Biosciences, Inc. announced the appointment of Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development, effective the same day. Dr. Cohen Pfeffer brings more than a decade of biopharmaceutical industry experience to the role.

Why it matters — SPRB watchers would note the addition of an experienced clinical development leader to the management team as the company advances its late-stage neurological therapy programs.

FAQ

Frequently asked questions about SPRB stock

What is the SPRB stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Spruce Biosciences, Inc. have a median 12-month price target of $142, with estimates ranging from $104 to $230. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SPRB stock a buy right now?

Of the 7 analysts covering Spruce Biosciences, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Spruce Biosciences, Inc. 28 out of 100 across roughly 4,600 US stocks as at 28 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SPRB?

As at 28 Aug 2026, Spruce Biosciences, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (76 of 100).

Will SPRB stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +133.6% from the last close, and Ticker Nerd's factor model ranks Spruce Biosciences, Inc. 28 out of 100 as at 28 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SPRB stock forecast for 2030?

No analyst covering Spruce Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPRB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $104 to $230 over the next 12 months.

What does Spruce Biosciences, Inc. do?

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for rare neurological and endocrine disorders with significant unmet medical need.

What is the latest news on SPRB?

The most recent item we track (Business Wire, 26 Aug 2026): "Spruce Biosciences Announces Launch of MPS3BStudy.com". Spruce Biosciences announced the launch of MPS3BStudy.com, a dedicated online resource for families and caregivers of children with Sanfilippo Syndrome Type B (MPS IIIB). The website allows users to learn about the condition and register their interest in the study.

Company

About Spruce Biosciences, Inc.

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for rare neurological and endocrine disorders with significant unmet medical need. Its current portfolio centers on enzyme replacement and small-molecule programs designed to address serious diseases where treatment options are limited or inadequate. The company’s work includes therapies for conditions such as Sanfilippo Syndrome Type B and congenital adrenal hyperplasia, reflecting its emphasis on targeted medicines for underserved patient populations. Spruce Biosciences, Inc. operates in the biotechnology sector and participates in the broader rare-disease market, where specialized clinical development and regulatory expertise are essential to bringing therapies to patients. Headquartered in South San Francisco, California, the company is positioned as a development-stage biopharmaceutical business concentrated on advancing precision treatments for complex disorders.

CEO Dr. Javier Szwarcberg M.D., M.P.H. · 22 employees · United States · https://sprucebio.com